

Non-Renounceable Rights Issue Offer Completes

Melbourne, Australia – 23 May 2024: Leading digital health company [Adherium Limited](#) (ASX:ADR), advises that the non-renounceable entitlement offer announced to the ASX on 26 April 2024 (**Offer**) closed on Monday, 20 May 2024.

The Offer was made to eligible shareholders registered on 2 May 2024 (**Eligible Shareholders**), on a 1 for 1 basis at \$0.02 per new share, to raise up to approximately \$6.8 million by the issue of up to approximately 340 million new shares together with 1 new free attaching option for every new share subscribed under the Offer.

Each new option is an unlisted option to acquire 1 fully paid ordinary share in the Company with an exercise price of \$0.03 and an expiry date of 30 June 2025.

Eligible shareholders who subscribed for their full entitlement under the Entitlement Offer were able to apply for additional securities on the same terms.

The Offer was fully underwritten by MST Financial Services Pty Ltd (**Underwriter**). If there remained any shortfall after allocation of entitlement to eligible shareholders under the Offer and Top-Up Offer, the Underwriter was able to subscribe or procure subscriptions for the shortfall in accordance with the terms of the Underwriting Agreement.

MST Financial Services Pty Ltd (**Lead Manager**) acted as lead manager to the Offer.

The results of the Offer are as follows:

	Shares	Options	Proceeds
Entitlement taken up	123,587,246	123,587,246	\$2,471,744.92
Additional Securities taken up	6,525,078	6,525,078	\$130,501.56
Shortfall to be placed with underwriter	209,926,657	209,926,657	\$4,198,533.14

The shortfall consisting of 209,926,657 shares and options will be placed to the Underwriter, eligible shareholders and sophisticated or professional investors introduced by the Lead Manager.

The Company has notified the Underwriter of the Shortfall and it is expected that the shares and options under the Offer will be issued progressively. The Lead Manager will be paid 6% of gross proceeds raised under the Offer. Further, options will be issued, equal in number to 1% of the issued capital of the Company as calculated on completion of the Offer, with an exercise price of \$0.04 each and an expiry date of three years from the date of issue.

Further, subject to shareholders' approval, new options will be issued equal in



ASX Release

number to 1% of the issued capital of the Company as calculated on completion of the Offer, with an exercise price of \$0.04 each and an expiry date of three years from the date of issue.

Learn more at adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

- ENDS -

Investor Enquiries

Dr. Paul Mastoridis
Adherium Limited
Chief Executive Officer
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK
Director
haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at adherium.com